Compare GFAI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | BLRX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | Singapore | Israel |
| Employees | 1698 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.6M |
| IPO Year | N/A | 2010 |
| Metric | GFAI | BLRX |
|---|---|---|
| Price | $0.61 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.8M | 10.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $2.30 |
| 52 Week High | $1.50 | $7.77 |
| Indicator | GFAI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 40.92 |
| Support Level | $0.55 | $2.66 |
| Resistance Level | $0.70 | $3.93 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 49.19 | 25.18 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.